Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges

Rutella, S. ORCID: 0000-0003-1970-7375, Cannarile, M.A., Gnjatic, S., Gomes, B., Guinney, J., Karanikas, V., Karkada, M., Kirkwood, J.M., Kotlan, B., Masucci, G.V., Meeusen, E., Monette, A., Naing, A., Thorsson, V., Tschernia, N., Wang, E., Wells, D.K., Wyant, T.L. and Cesano, A., 2020. Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges. Journal for ImmunoTherapy of Cancer, 8 (2): e001389. ISSN 2051-1426

[img]
Preview
Text
1383370_Rutella.pdf - Published version

Download (308kB) | Preview

Abstract

The sharing of clinical trial data and biomarker data sets among the scientific community, whether the data originates from pharmaceutical companies or academic institutions, is of critical importance to enable the development of new and improved cancer immunotherapy modalities. Through data sharing, a better understanding of current therapies in terms of their efficacy, safety and biomarker data profiles can be achieved. However, the sharing of these data sets involves a number of stakeholder groups including patients, researchers, private industry, scientific journals and professional societies. Each of these stakeholder groups has differing interests in the use and sharing of clinical trial and biomarker data, and the conflicts caused by these differing interests represent significant obstacles to effective, widespread sharing of data. Thus, the Society for Immunotherapy of Cancer (SITC) Biomarkers Committee convened to identify the current barriers to biomarker data sharing in immuno-oncology (IO) and to help in establishing professional standards for the responsible sharing of clinical trial data. The conclusions of the committee are described in two position papers: Volume I-conceptual challenges and Volume II-practical challenges, the first of which is presented in this manuscript. Additionally, the committee suggests actions by key stakeholders in the field (including organizations and professional societies) as the best path forward, encouraging the cultural shift needed to ensure responsible data sharing in the IO research setting.

Item Type: Journal article
Publication Title: Journal for ImmunoTherapy of Cancer
Creators: Rutella, S., Cannarile, M.A., Gnjatic, S., Gomes, B., Guinney, J., Karanikas, V., Karkada, M., Kirkwood, J.M., Kotlan, B., Masucci, G.V., Meeusen, E., Monette, A., Naing, A., Thorsson, V., Tschernia, N., Wang, E., Wells, D.K., Wyant, T.L. and Cesano, A.
Publisher: BioMed Central
Date: October 2020
Volume: 8
Number: 2
ISSN: 2051-1426
Identifiers:
NumberType
10.1136/jitc-2020-001389DOI
1383370Other
Rights: Copyright information: © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Divisions: Schools > School of Science and Technology
Record created by: Linda Sullivan
Date Added: 02 Nov 2020 12:03
Last Modified: 02 Nov 2020 12:03
URI: http://irep.ntu.ac.uk/id/eprint/41454

Actions (login required)

Edit View Edit View

Views

Views per month over past year

Downloads

Downloads per month over past year